• Phase

    Startup

  • Website
  • Area

Aventera

Aventera Antibodies develops first-in-class monoclonal antibody therapies targeting invasive Group A Streptococcus. Founded in 2025 with LU Ventures, we are a spin-off built on over 10 years of research at Lund University’s Faculty of Medicine. We aim to turn deep scientific expertise into life-saving treatments.

© 2023 Copyright SmiLe Incubator